SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-AJ-00012
Product Name	Carbetamide
CAS No.	16118-49-3
Category	Pesticide Standards
Synonyms	Not available
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email **sales@clearsynth.com** for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Acute toxicity (Category 4)

2.2 Label Elements

Signal Word: Warning

Hazard Statement(s)

Code	Statement
H302	Harmful if swallowed.
H351	Not available
H411	Toxic to aquatic life with long lasting effects.
H360	Not available

Precautionary Statement(s)

Code	Statement
P203	Not available
P264	Wash hands thoroughly after handling.
P270	Not available
P273	Not available
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P301+P317	Not available
P318	Not available
P330	Not available
P391	Not available
P405	Store locked up.
P501	Dispose of contents/container in accordance with local/regional/national/international regulatio

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Carbetamide
CAS Number : 16118-49-3
Molecular Formula : C12H16N2O3
Molecular Weight : 236.27
Parent Chemical : -
Synonyms : Not available
Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures
- General advice: Remove contaminated clothing and shoes. Seek medical attention if symptoms persist or develop.
- Inhalation: Move person to fresh air. Keep at rest. Get medical attention if symptoms occur.
- Skin contact: Wash with plenty of soap and water. Get medical attention if irritation persists.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Get medical attention if irritation persists.
- Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Get medical attention.

4.2 Most important symptoms/effects, acute and delayed
- Not available.

4.3 Indication of immediate medical attention and special treatment needed
- Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Suitable extinguishing media
- Use extinguishing measures appropriate to surrounding fire (water spray, dry chemical, foam, carbon dioxide).

5.2 Special hazards arising from the substance or mixture
- No data available. Combustion may produce irritating and/or toxic fumes.

5.3 Advice for firefighters
- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Cool containers with water spray if exposed to fire.
- Prevent fire-fighting water from entering drains or waterways.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
- Avoid dust formation and breathing dust.
- Use appropriate personal protective equipment (see Section 8).
- Ensure adequate ventilation.

6.2 Environmental precautions
- Avoid release to the environment. Prevent entry into drains, surface water, and soil.

6.3 Methods and material for containment and cleaning up
- Collect spilled material using methods that minimize dust generation.
- Place in a suitable, labeled container for disposal.
- Clean spill area with water and detergent where appropriate; avoid generating airborne dust.

6.4 Reference to other sections
- See Section 8 for exposure controls/personal protection and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling
- Avoid contact with skin and eyes.
- Avoid breathing dust; avoid dust generation.
- Use with adequate ventilation.
- Wash hands thoroughly after handling.
- Do not eat, drink, or smoke when using this product.

7.2 Conditions for safe storage, including any incompatibilities
- Store in tightly closed container.
- Store in a cool, dry, well-ventilated place.

- Protect from moisture.
- Incompatible materials: Not available.

7.3 Specific end use(s)
- Pesticide standard / laboratory use. No further information available.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters
- Occupational exposure limits: Not available.
- Biological limit values: Not available.

8.2 Exposure controls
- Engineering controls: Provide adequate ventilation. Use local exhaust where dust may be generated.
- Personal protective equipment (PPE):
- Eye/face protection: Safety glasses with side shields or chemical splash goggles.
- Skin protection: Protective gloves. Wear protective clothing as appropriate.
- Respiratory protection: If ventilation is inadequate or dust is generated, use a suitable particulate respirator per applicable standards.
- Hygiene measures: Wash hands after handling. Remove contaminated clothing and wash before reuse.
- Environmental exposure controls: Avoid release to the environment.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available

Property	Value
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity
- No data available.

10.2 Chemical stability
- Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions
- No data available.

10.4 Conditions to avoid
- Avoid dust formation. Avoid heat and sources of ignition as a general precaution.

10.5 Incompatible materials
- Not available.

10.6 Hazardous decomposition products
- No data available. Thermal decomposition may produce irritating and/or toxic fumes.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Acute toxicity: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms

such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).
- Aspiration hazard: No data available.

Likely routes of exposure
- No data available.

Symptoms related to the physical, chemical and toxicological characteristics
- Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine

receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity
- No data available.

12.2 Persistence and degradability
- No data available.

12.3 Bioaccumulative potential
- No data available.

12.4 Mobility in soil
- No data available.

12.5 Results of PBT and vPvB assessment
- Not available.

12.6 Endocrine disrupting properties
- No data available.

12.7 Other adverse effects
- No data available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods
- Dispose of contents/container in accordance with local/regional/national/international regulations.
- Do not discharge to drains or the environment.
- Contaminated packaging: Dispose of as unused product unless cleaned according to applicable regulations.
- Waste code: Not available.

SECTION 14: Transport information

SECTION 14: Transport information

- UN number: Not available.
- UN proper shipping name: Not available.
- Transport hazard class(es): Not available.
- Packing group: Not available.
- Environmental hazards: Not available.
- Special precautions for user: Not available.
- Transport in bulk according to IMO instruments: Not available.

Note: Transport classification may vary by mode and jurisdiction; confirm with current regulatory requirements and carrier.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
- Not available.

15.2 Chemical safety assessment
- No data available.

SECTION 16: Other information

SECTION 16: Other information

- Product name: Carbetamide
- CAS No.: 16118-49-3
- Catalog No.: CS-AJ-00012
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

Disclaimer: The information provided is based on available product identification details and is intended for SDS-style guidance. No warranty is expressed or implied. Users are responsible for compliance with applicable laws and regulations and for determining suitability for their particular use.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.